The positive Phase 2 data and secured financing remove major overhangs; watch for Phase 3 trial initiation and potential partnership announcements. The dilution from the offering is a near-term headwind but the cash runway supports value creation through data milestones.
Price Chart
Executive Summary
Avalo Therapeutics reported Q1 2026 results with a narrower-than-expected EPS loss of -$0.98 (vs consensus -$1.00) and highlighted positive Phase 2 LOTUS data for abdakibart in hidradenitis suppurativa. The company completed a $431.3M public offering, extending cash runway into 2029, and plans to advance to a registrational Phase 3 program.
Key Financial Metrics
Key Facts
- Phase 2 LOTUS trial met primary endpoint (HiSCR75) at both doses (p<0.02) with 42%+ absolute improvement over placebo (42.5% combined vs 25.6% placebo).
- Completed underwritten public offering on May 7, 2026 for gross proceeds of $431.3M ($405M net).
- Q1 2026 net loss $19.6M vs $13.1M in Q1 2025; basic EPS -$0.98 vs -$1.25 YoY (improved due to higher share count).
- Cash, cash equivalents and short-term investments $82M as of Mar 31, 2026; pro forma cash ~$487M (including May offering) funds operations into 2029.
- Entered Milestone Buyout Option for $2.25M to cap $15M milestone payment upon Phase 3 first patient dosing.
Financial Impact
EPS beat of ~2% vs consensus; net loss widened $6.5M YoY, but the key catalyst is clinical data and financing. The $431.3M offering is significantly dilutive (shares outstanding increased >30% since Dec 2025).
Risk Factors
- Phase 3 trial may fail to replicate Phase 2 results.
- Significant dilution from $431M offering; weighted average share count more than doubled YoY.
- No revenue; entirely dependent on pipeline success and further capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001534120-26-000032 |
| Document: avtx-20260513.htm | 0001534120-26-000032 |
| Document: 0001534120-26-000032-index-headers.html | 0001534120-26-000032 |
| Document: 0001534120-26-000032-index.html | 0001534120-26-000032 |
| Document: 0001534120-26-000032.txt | 0001534120-26-000032 |
| 8-K Data (Synthetic) | 0001534120-26-000032 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $20.75 $16.69 | ▼ −19.57% | ▼ −17.61% | $14.99 (−27.76%) |
Aug 17, 2026 6w ago | Institutional Cluster | $19.95 $16.07 | ▼ −19.45% | ▼ −17.47% | $14.99 (−24.86%) |
Aug 6, 2026 8w ago | 8-K | $18.70 $19.00 | ▲ +1.60% | ▲ +1.00% | $14.99 (−19.84%) |
Jun 16, 2026 15w ago | 8-K | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 16, 2026 15w ago | Press Release | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 8, 2026 16w ago | 8-K | $12.90 $19.25 | ▲ +49.22% | ▲ +47.78% | $14.99 (+16.20%) |
May 13, 2026 20w ago | 8-K | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 13, 2026 20w ago | Press Release | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 6, 2026 21w ago | Press Release | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
May 6, 2026 21w ago | Insider Cluster | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access